A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic properties of previously mapped antigenic sites and represents the amino-terminal region of viral protein VP2. As with marker vaccines, it is possible to discriminate between vaccinated dogs that have not been exposed to the virus and dogs that have been infected with the virus. The protective mechanism can be explained by a humoral response against the peptide aided by T-cell epitopes contained in the carrier protein used for peptide coupling. This is the first example of a synthetic peptide vaccine that induces protection in target animals.
A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic properties of previously mapped antigenic sites and represents the amino-terminal region of viral protein VP2. As with marker vaccines, it is possible to discriminate between vaccinated dogs that have not been exposed to the virus and dogs that have been infected with the virus. The protective mechanism can be explained by a humoral response against the peptide aided by T-cell epitopes contained in the carrier protein used for peptide coupling. This is the first example of a synthetic peptide vaccine that induces protection in target animals.
Vaccines based on synthetic peptides would be safe and easy to produce. They would circumvent the risks in handling and spreading of the infectious agent inherent to conventional vaccines, and they would offer advantages over biologically produced vaccines, namely, reproducibility, exclusion of contaminating microorganisms, and stability. A considerable number of synthetic peptides which induce neutralizing antibodies (4-6, 16, 23, 25, 41, 54, 55) and, to a variable extent, protection in the natural host (14, 15, 20, 22, 26, 35, 38, 50, 52, 56) have been described. However, none has yielded sufficient protection for application in a vaccination program. An important reason for this is that viral domains prone to neutralization behave as mutational hot spots, especially in RNA viruses (24, 53) , with the small nonenveloped picornavirus foot-and-mouth disease virus and the complex retrovirus human immunodeficiency virus type 1 being extensively studied examples (9, 17, 21, 32) . Although these data have led to the general belief that it is unrealistic to try to develop useful peptide vaccines, it remains theoretically possible that full protective responses could be achieved if the amino acid sequences used were based on parts of the viral particle that are not prone to mutation but are vital for its survival. We report here the validity of this assumption in canine parvovirus (CPV).
CPV is one of the autonomously replicating members of the Parvoviridae family, which are small (25-nm-diameter), nonenveloped, single-stranded DNA viruses (51) . The DNA sequences of CPV and its highly homologous host range variants isolated from cats, minks, and raccoons appear to be conserved under field conditions (>98% homology) (33, 36, 37, 42, 43) . The viral capsid is composed of 60 protein subunits, of which about 10% are VP1 and the remainder are VP2 and VP3 in variable proportions (12, 57) . Proteins VP1 (748 amino acid residues) and VP2 (584 amino acid residues) are derived from the same gene by differential splicing, and VP3 is derived from VP2 by proteolytic removal of about 20 amino acids from the N terminus. Therefore, the entire amino acid sequences of VP2 and VP3 are contained within the C terminus of VP1 (summarized in reference 12). While the spatial structure of most of the VP2 domain is known from X-ray diffraction analyses, the spatial structure of the amino-terminal 37 residues remains unknown because of its disordered state (1, 57) . The amino acid sequences of this part of VP2 are completely identical in all CPV isolates and host range variants from cats, minks, and raccoons which have been analyzed (33, 37, 42, 43) . The role and dynamics of the N terminus of VP2 in parvoviruses are subject to speculation. However, the domain is important because of the following observations. (i) Virus neutralization has been observed in vitro with a monoclonal antibody directed against this site (30) . (ii) It is immunogenic in several animal species (27) . (iii) It is involved in in vitro cell entry after the virus has attached to the membrane of the host cell (at least in the homologous parvovirus minute virus of mice [58] ). The peptide vaccine described here is directed against a part of this site.
As with other parvoviruses, CPV replication is the most deleterious in actively dividing tissues (36) . For dogs that do not have antibodies against the virus, the consequences of infection, namely, myocarditis in puppies less than 10 weeks old and severe enteritis later on, are devastating. Resistance against the disease is controlled by humoral immunity (for a review, see reference 36). We report here that in young dogs, effective protection of all animals (nine individuals tested) against canine parvovirus was obtained with a synthetic peptide vaccine. The selection of the sequence was based on a previous search for neutralization-inducing activity of synthetic peptides in rabbits (26a). The protective effect was provided by the antipeptide antibodies which appeared to be dependent on T-cell epitopes present in the carrier protein. To our knowledge, this is the first report of host protection induced by a synthetic peptide vaccine which can comply with requirements for practical application.
MATERIALS AND METHODS
Animals. New Zealand White rabbits were from Charles River (Sulzfeld, Germany). Specified-pathogen-free (SPF) fe- Peptides. Two peptides, il15 and 7L15, with the partially overlapping sequences MSDGAVQPDGGQPAV and QPDG GQPAVRNERAT, respectively, were used in this study. They were synthesized on Rink resin (0.1-mmol scale, 0.48 milliequivalent/g). Couplings were carried out with Fmoc-amino acids (3 equivalents) in the presence of PyBOP (3 equivalents), N-hydroxybenzoltriazole (3 equivalents), and diisopropylethylamine (6 equivalents). The procedures for synthesis and deprotection were based on established methods (11, 47) . The syntheses were performed either manually in glass vessels or on an Applied Biosystems 430A synthesizer using Fastmoc chemistry (19) . Peptides were synthesized with a cysteine at the amino terminus for coupling with KLH and with the N and C termini in the acetylated and amidated forms, respectively, and were analyzed by high-performance liquid chromatography on a C18 reversed-phase column (150 by 4.6 mm; bead diameter, 5 ,um; Supelcosil LC-18-DB; Supelco) using photodiode array detection. A linear gradient of methanol from 10 to 80% (1%/min) in 0.1% trifluoroacetic acid in water at 30°C at a flow rate of 1 ml/min was used. Peptides were purified on a C18 reversed-phase column ( hydroxide gel (final volume, 1.6 ml). Two consecutive vaccination experiments were performed with 3 dogs in the first experiment and 10 dogs in the second experiment ( Table 1 ).
The animals received the preparations by subcutaneous injection on days 1 and 30. Control dogs received placebo preparations containing amounts of KLH, QuilA, and aluminium hydroxide equivalent to those used for the vaccinated dogs. On day 72, the animals were exposed to challenge with CPV on their eyes, noses, and mouths (2.5 ml). The condition, eating habits, and rectal temperatures of the dogs were monitored weekly or, during the experimental infection, daily. Blood samples for preparation of serum and peripheral blood mononuclear cells (PBMC) were collected at various times before and during vaccination and after challenge. For immunization of rabbits as reference animals, the immunization cocktail (total volume, 2 ml) consisted of the same mixture of KLHconjugated peptides iL15 and 7L15 as used in the dogs, adsorbed to aluminium hydroxide plus QuilA, and was administered by subcutaneous and intramuscular routes. On day 42, the animals received a second injection of the same cocktail.
Peptide ELISA for detection of peptide-specific antibodies and PEPSCAN. For peptide ELISA, all incubations were carried out with 100-,ul volumes in the wells of polystyrene microtiter plates and washes were performed between each step with 0.05% (wt/vol) Tween 80 in phosphate-buffered saline (PBS). The wells of polystyrene plates (Greiner, 665101)
were coated with peptides overnight at 4°C at 10 ,ug/ml in 50 mM Na-carbonate solution, pH 9.6. For incubation with the first antibody, rabbit or dog sera were diluted in incubation buffer, which consisted of 4% (vol/vol) horse serum, 1% (wt/vol) Tween 80, and 0.5 M NaCl in PBS, and incubated for 1 h at 25°C. The second antibody incubation was at 25°C with anti-rabbit or anti-dog Ig peroxidase diluted 1/1,000 in incubation buffer. Color was developed with tetramethylbenzidine and stopped after 20 min with H2SO4. A450 was measured.
Sera from dogs were tested with a PEPSCAN procedure as previously described, using the same set of solid-phase nonapeptides representing the entire 748 residues of VP1 (27) .
ELISA for detection of CPV-specific antibodies. Two different methods were used to detect CPV-specific antibodies: an indirect and a competitive anti-CPV ELISA. For the indirect anti-CPV ELISA, the wells of plates (Polysorb; Nunc, Roskilde, Denmark) were coated with purified CPV at 1 ,ug/ml in 0.5 M Na-carbonate buffer (pH 9.6) overnight at 4°C. Washes between consecutive steps were carried out with 0.05% (wt/ vol) Tween 20 in physiological saline (Tween-saline). Coated plates were incubated for 2 h at 37°C with dog or rabbit sera diluted in 2% (wt/vol) bovine serum albumin in Tween-saline.
After the plates were washed, they were further incubated with anti-rabbit or anti-dog Ig peroxidase conjugate in 2% (wt/vol) bovine serum albumin in Tween-saline for 1 h at ambient temperature. Color was developed with 100 ,ul of o-phenylenediamine (1 mg/ml) in a solution of 24.3 mM citric acid, 51.4 mM Na2HPO4, and 0.012% (vol/vol) H202 and within 30 min stopped by the addition of 50 ,ul of 1.5 M H2SO4. A495 was measured.
Competitive anti-CPV ELISA was performed as previously VOL. 68, 1994 described (46) . In this assay, plates coated with CPV antigen were incubated with a mixture of dog serum samples (at different concentrations) and a constant amount of CPVspecific monoclonal antibodies conjugated to horseradish peroxidase.
DAS ELISA for the detection of CPV antigen. The presence of CPV antigen in fecal samples was investigated with doubleantibody sandwich (DAS) ELISA as previously described (46) .
In vitro neutralization and hemagglutination inhibition (HI). Neutralizing activity of sera was determined by assaying the CRFK cell monolayer protection activity as previously described (30) supplemented with penicillin (100 IU/ml), streptomycin (100 ,ug/ml), L-glutamine (2 mM), 3-mercaptoethanol (2 x 102 mM), and 10% heat-inactivated SPF dog sera (negative for CPV antibodies). In addition, fresh autologous gamma-irradiated (with 3,000 rads) PBMC, isolated at 90 dpi after immunization, were added as feeder cells at a concentration of 1.5 Course of antibody production by vaccination. In all vaccinated animals, antipeptide and anti-CPV antibody titers were nearly maximal at 2 weeks after the first immunization, rose marginally within the next 10 days after the booster injection, and then gradually declined ( Fig. la and b) . Serum neutralizing activity in the first vaccination experiment, as measured by monolayer protection test, also appeared within 2 weeks and was maximal between weeks 3 and 6, but then the titers dropped below the detection level in the remaining preinfection period (Fig. ic) . In the second experiment, none of the dogs developed detectable in vitro neutralizing activity before challenge (not shown). The control dogs remained seronegative until seroconversion 6 dpi ( Fig. lb and c) .
Protection against challenge. Experimental exposure with a fecal CPV preparation led to severe infection of all four control dogs (Table 1) , while the vaccinated animals remained clinically healthy. The clinical signs in the control dogs were anorexia, weakness, diarrhea, and severe intestinal hemorrhage (blood in the stool), which are typical CPV manifestations (39) . The results of histologic examinations of these dogs were in accordance with parvovirus infection. Analysis of extracts from the intestinal tract for the presence of CPV by established procedures (45) showed that the infection was caused by CPV and not by other agents (e.g., canine coronavirus). Of the four control dogs, one died at 6 dpi, another died the next day, and the remaining two were euthanized on the same day to stop further suffering. No anti-CPV antibodies could be detected in any of the serum samples of the control dogs except from 6 dpi (Fig. 1) . Massive excretion of CPV in the feces of these dogs was observed at 4 and 5 dpi, while in four of nine vaccinated dogs, only a very low level of CPV on 5 dpi was found (Fig. 2) . Body temperatures were elevated in all control dogs on 4 dpi (above the normal fluctuation maximum of 39 .6°C) and in five of nine vaccinated animals on 5 or 6 dpi. Although this is an indicator for CPV infection (39), none of the dogs vaccinated with the peptide vaccine became clinically ill or showed any sign of disease, including loss of appetite. Therefore, the vaccine efficiently protects dogs against infection with virulent CPV.
Neutralization blocking experiments. The induction of in vitro neutralizing activity in both nonvaccinated and vaccinated dogs shortly after challenge (6 to 10 dpi [ Fig. 1]) , suggested the occurrence of an additional class of neutralizing antibodies directed to epitopes other than the linear neutralization site in the VP2 N terminus. This was confirmed with neutralizing antisera of dogs from the first vaccination experiment by preincubation with the peptides used for vaccination (Table 2) . Before challenge, neutralizing activity in sera from vaccinated dogs could be completely blocked. However, after challenge, no blocking by the peptides was observed.
T-cell proliferation. The protective effect of vaccination with peptides conjugated to KLH raised the question about the origin of T-cell epitopes mediating the humoral response. The proliferative activity of PBMC in vaccinated animals was assayed as [3H]thymidine incorporation at the following five times: before vaccination, before challenge, and after infection at 9, 30, and 90 dpi (Fig. 3) . Before and after challenge, T-cell activity was observed when KLH was present as the antigen, either free or conjugated to the peptides. After challenge, CPV antigen was also able to induce a T-cell response, but this was only obvious from 30 dpi on (while antibody titers were already elevated at 8 dpi [ Fig. 1 and 3 aTwo similar vaccination experiments were performed at different times with newly prepared peptides. In the first experiment, three 13-week-old female dogs were kept in separate cages and one of the dogs served as a control. In the second experiment, 10 15-week-old animals (4 females and 6 males) were used, housed in three groups and one group (one female and two males) served as a control group.
" Each dose of the vaccine contained 1 mg each of peptides IL15 and 7-15; 80 to 300 ,ug of each peptide was covalently bound to KLH, as determined by amino acid analysis (see also Materials and Methods). activity (HI). In general, CPV neutralizing antibodies also have HI activity, but one monoclonal anti-CPV antibody (3C9) with a strong neutralizing effect does not. This antibody was shown to bind to the sequence QPAVR within the 21 N-terminal residues of VP2 (27) . The neutralizing antipeptide antibodies from vaccinated dogs taken before challenge did not have HI activity (Table 3) , and the neutralizing rabbit antipeptide sera also did not have HI activity (not shown). The challenge with virus induced HI activity from 6 dpi on in vaccinated dogs and also control dogs. Thus, with an HI assay and ELISA (Table 3 ; Fig. 1 ), it is possible to discriminate between animals which had been vaccinated with the synthetic peptide vaccine and were not exposed to the virus (positive only by ELISA) and animals which had been infected (positive by both ELISA and HI).
Sequence specificity of antibodies from vaccinated dogs. Previously, a linear site (SDGAVQ at positions 2 to 7 of VP2) was recognized by three (of six) serum samples from dogs naturally infected with CPV when analyzed in a PEPSCAN on solid-phase synthetic peptides (27) . This group of serum samples was later extended with 12 Before immunization (day 0) < < < < < < After 2nd vaccination (day 43) < 800 < 800 < < After challenge (6-10 dpi) 800 800 1,600 1,600 800 800
Sera were taken from dogs in experiment 1 ( Table 1) . "Values are given as titers of neutralization determined in monolayer protection test. Symbols: + and -indicate incubation with and without peptides IL15 plus 7L15, respectively (see also Materials and Methods); <, no detectable neutralizing activity (the lowest dilution measured was 1/10).
bound to sequences in the N-terminal domain of VP2. These results indicate that the domain is not an immunodominant site on the virus. On the other hand, the sera from the dogs vaccinated with the peptides, taken either before or after the challenge, bound to the N-terminal domain at another site (DGGQPAVR at positions 9 to 16 of VP2) (Fig. 4) .
DISCUSSION
In this report the first synthetic peptide vaccine which yields protection in the target animal is described. Protection in dogs was obtained with two overlapping peptides representing the 21-residue-long N terminus of VP2 of canine parvovirus. The " The results of the two immunochemical tests are expressed as titers. <, below the detection level.
In the HI assay, the lowest dilution tested was 1/4. In experiment 2, HI activity (titer of >16) also started to appear from 6 dpi on in all animals (not shown).
" In the competitive CPV ELISA, the lowest serum dilution tested was 1/40. These samples were taken at day 78 because dog 3 died at day 78 (6 dpi). (27) (10, 27) . (iv) The N terminus of VP2 is a conserved domain in the different isolates from dogs, cats, minks, and raccoons (33, 37, 42, 43) .
CPV contains more than one site for neutralization. With murine monoclonal antibodies, several neutralization sites have been localized on the viral surface (8, 27, 30, 37, 44) . For the target animals, there is now also evidence for the existence of multiple neutralization sites on CPV, based on the blocking studies with the neutralizing dog sera and peptides ( Table 2 ). The peptide used in this study does not appear to be part of an immunodominant site. This leads us to speculate about the potential of the vaccine for induction of immunity in the presence of antivirus antibodies (see below).
After challenge, the vaccinated dogs undergo a subclinical CPV infection, which is probably the result of very limited abortive viral replication. This is based on the following observations: seroconversion occurred within 10 dpi in HI and neutralization blocking assays, body temperature was elevated in a number of animals at 5 or 6 dpi, and some fecal samples at 5 dpi contained a very low level of CPV antigen (Tables 2  and 3 ; Fig. 2 to 4 ). Such effects were expected. Animals vaccinated with inactivated CPV excrete some virus after challenge, even if they had already a low level of preexisting anti-CPV antibodies (18) . Even when compared with other studies (2, 39) , the challenge we used was extraordinarily devastating for the SPF control animals. Nevertheless, vaccinated animals were fully protected against disease, which proves the efficacy of this peptide vaccine.
The protection obtained in our experiments seems to be mediated by antipeptide antibodies (i.e., directed against the N terminus of VP2), while T-cell responses hardly play a role at the time of infection. The T-cell epitopes involved appeared to be localized not in the peptides but within the carrier protein KLH. Thus, the protection of the dogs by vaccination with the peptide vaccine must have proceeded through the humoral immune system in accordance with other studies using antibodies directed against whole CPV (34, 36, 39) .
An advantage of the peptide vaccine described in this report is the possibility of designing tests which discriminate between vaccinated and infected animals. With the HI test, animals which had been infected with virus could be distinguished from vaccinated animals before experimental infection (Table 3) . Alternative tests could obviously be developed, as is evident from the blocking experiments, in which antibody binding could be inhibited by the peptides used for vaccination only in the sera taken before seroconversion (Table 2) . Such discriminatory tests are useful in programs to eradicate pathogenic viruses like that applied with the veterinary marker vaccine for pseudorabies virus infection in swine (59) . They can also be of importance in the surveillance of the occurrence of a virus, for which vaccination with peptides might become available.
Another advantage of the synthetic peptide vaccine over classical vaccines is its potential to overcome the nonresponsiveness to vaccination in young animals that is caused by the presence of small residual amounts of maternal antibodies which neutralize the live attenuated viruses used in conventional vaccines. Conventional vaccination against CPV in puppies younger than 10 weeks of age does not guarantee protection because they have maternally derived antibodies (40) , which were raised against whole virus. If the antibodies against the peptide antigens of CPV are not among the maternally derived antibodies, the peptide vaccine would allow triggering of the immune system in the neonate at a much earlier stage than is possible under present conditions. Our PEPSCAN data suggest that indeed among the antibodies directed against whole virus in infected control animals, the antipeptide antibodies are probably not present.
Our results show for the first time that a peptide vaccine is just as efficacious as the classical vaccine prepared from whole virus. The question arises whether this approach also applies to other pathogens. Since CPV is a DNA virus, we speculate that at least for those viruses with low mutation rates, the minimal requirements for full protection might be less stringent than for RNA viruses. Because of this and the high homology between the host range variants of CPV, feline panleukopenia virus, mink enteritis virus, and raccoon parvovirus, we expect that cats, minks, and raccoons will be equally well protected when given a similar peptide vaccine. Furthermore, it is likely that this approach is applicable for other parvoviruses for which vaccination is desirable such as porcine parvovirus and human B19 parvovirus (3, 31) . It was recently shown that a recombinant B19 capsid peptide with the amino acid sequence of the N terminus of VP2 also induced neutralizing antibodies (48) , indicating that this domain is a general site for neutralization in autonomously replicating parvoviruses. The 
